Interpace Diagnostics Group’s (IDXG) “Buy” Rating Reaffirmed at Maxim Group

Maxim Group reissued their buy rating on shares of Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) in a report issued on Tuesday. They currently have a $5.00 price objective on the business services provider’s stock.

Separately, ValuEngine raised Interpace Diagnostics Group from a strong sell rating to a sell rating in a research report on Monday, September 11th.

Shares of Interpace Diagnostics Group (NASDAQ:IDXG) opened at $1.22 on Tuesday. The company has a market capitalization of $32.49, a P/E ratio of 0.43 and a beta of 1.61. Interpace Diagnostics Group has a 12 month low of $0.70 and a 12 month high of $19.80.

WARNING: “Interpace Diagnostics Group’s (IDXG) “Buy” Rating Reaffirmed at Maxim Group” was first posted by BBNS and is owned by of BBNS. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://baseballnewssource.com/markets/interpace-diagnostics-groups-idxg-buy-rating-reaffirmed-at-maxim-group/1782884.html.

A hedge fund recently bought a new stake in Interpace Diagnostics Group stock. Susquehanna International Group LLP bought a new stake in Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 718,076 shares of the business services provider’s stock, valued at approximately $646,000. Susquehanna International Group LLP owned approximately 3.84% of Interpace Diagnostics Group at the end of the most recent quarter. 7.15% of the stock is currently owned by institutional investors.

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

Receive News & Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.